Experimental treatments for asthma

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 1, 1997, Pages 30-41

  Floreani, Anthony A ^a   Rennard, Stephen I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; BRADYKININ; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHYMASE; CHYMASE 2; CYCLOSPORIN; DIURETIC AGENT; HEPARIN ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; KININ; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIDOCAINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ A; NEW DRUG; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN SYNTHASE; SERINE PROTEINASE; TACHYKININ RECEPTOR; TRYPTASE;

ASTHMA; DRUG ANTAGONISM; GENE THERAPY; HUMAN; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; REVIEW; T LYMPHOCYTE;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ASTHMA; AURANOFIN; BRADYKININ; CHOLINERGIC ANTAGONISTS; CHYMASES; CYCLOSPORINE; DIURETICS; DRUGS, INVESTIGATIONAL; GENE THERAPY; HEPARIN ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KININS; LEUKOTRIENE ANTAGONISTS; LIDOCAINE; MUSCARINIC ANTAGONISTS; NEUROKININ A; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, TACHYKININ; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES; TRYPTASES;

EID: 0030640238     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199701000-00006     Document Type: Article

References (108)

1. National Heart, Lung, and Blood Institute: National Asthma Education Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Bethesda, 1991.
2. Henderson WR: The role of leukotrienes in inflammation. Ann Intern Med 1994, 121:684-697.
3. Pauwels RA, Joos GF, Kips JC: Leukotrienes as therapeutic target in asthma. Allergy 1995, 50:615-622.
4. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993, 341:989-990.
5. 4 levels following allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991, 144:1411-1413.
6. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB: Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989, 84:19-26.
7. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY: Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990, 142:112-119.
8. 4 and histamine in asthmatics. Am Rev Respir Dis 1992, 146:96-103.
9. Holgate ST, Bradding P, Sampson AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996, 98:1-13. An excellent review of the leukotriene biosynthesis inhibitors and receptor antagonists, including their possible role in the management of asthma. The authors include data from effects of these compounds on baseline lung function, allergen challenge, and in clinical trials.
10. 4 induces interleukin 5 generation from human T lymphocytes. Eur J Immunol 1993, 23:2392-2398.
11. 4 enhances IL-4-induced IgE production from normal human lymphocytes. Cell Immunol 1994, 156:124-134.
12. Nasser SMS, Bell GS, Hawkswor Th RJ, et al.: Effect of The 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994, 49:743-748.
13. Hui KP, Taylor IK, Taylor GW, et al.: Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991, 46:184-189.
14. Kane GC, Pollice M, Kim C-J, et al.: A controlled trial of the effect of The 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996, 97:646-654.
15. Israel E, Rubin P, Kemp JP, et al.: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993, 119:1059-1066.
16. Israel E, Cohn J, Dube L, Drazen JM: Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996, 275:931-936.
17. Diamant Z, Timmers MC, van der Veen H, et al.: The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995, 95:42-51.
18. Virchow JC, Noller PS, WieBmann KJ, et al.: Multicenter trial of Bay X 1005: a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma [abstract]. Am Rev Respir Dis 1995, 151:A377.
19. 4 antagonism in a primate model of asthma. J Clin Invest 1996, 97:381-387.
20. Chung KF: Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995, 8:1203-1213. An excellent and very thorough review of this area. The authors provide summary tables for major effects of drugs in clinical evaluation. Allergen challenge, clinical studies in asthma, and multiple dosing studies are included in this comprehensive review.
21. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT: Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991, 337:690-694.
22. 4 receptor antagonist ICI 240,219 against exercise-induced asthma. Am Rev Respir Dis 1993, 147:1413-1418.
23. Nathan RA, Glass M, Minkwitz MC: Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994, 105:483-488.
24. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993, 147:1431-1435.
25. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990, 141:988-992.
26. Spector SL, Smith LJ, Glass M: Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994, 150:618-623.
27. Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y: Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994, 150:254-257.
28. 4-receptor antagonist. N Engl J Med 1990, 323:1736-1739.
29. Dahlen B, Kumlin M, Margolskee DJ, et al.: The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin sensitive asthmatics. Eur Respir J 1993, 6:1018-1026.
30. 2 on excitatory neuro-effector transmission in the human bronchus. Prostaglandins 1990, 39:639-655.
31. Peters SP, Schulman ES, MacGlashan DW, Schleimer RP, Newball HH, Lichtenstein LM: Pharmacological and biochemical studies of human lung mast cells. J Allergy Clin Immunol 1982, 69:150.
32. 2 on allergen-induced asthma. Am Rev Respir Dis 1993, 148:87-90.
33. 2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994, 149:A1055.
34. Barnes PJ, Baraniuk JN, Belvisi MG: Neuropeptides in the respiratory tract. Am Rev Respir Dis 1991, 144:1187-1198.
35. Barnes PJ: Neuropeptides and asthma. Am Rev Respir Dis 1991, 143(suppl):S28-S32.
36. Baraniuk JN, Ohkubo K, Kwon OJ, et al.: Localization of neutral endopeptidase (NEP) mRNA in human bronchi. Eur Respir J 1995, 8:1458-1464.
37. Ollerenshaw S, Jarvis D, Woolcock A, Sullivan C, et al.: Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med 1989, 320:1244-1248.
38. Kudlacz EM, Burkholder TP, Shatzer S, Kippenberg R, Farrell A, Logan D: In vitro and in vivo characterization of MDL 103,392A, an orally active, non-peptide NK-1/NK-2 receptor antagonist [abstract]. Am J Respir Crit Care Med 1995, 151:A106.
39. Girard V, Naline E, Vilain P, Amonds-Alt X, Advenier C: Effect of the two tachykinin antagonists, SR 48968 and SR 140333, on cough induced by citric acid in the unanaesthetized guinea-pig. Eur Respir J 1995, 8:1110-1114.
40. 1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995, 152:879-884.
41. Bianco S, Pieroni MG, Refini RM, Robuschi M, Vaghi A, Sestini P: Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur Respir J 1993, 6:130-134.
42. Bianco S, Pieroni MG, Refini RM, Rottoli L, Sestini P: Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med 1989, 321:1069-1073.
43. Polosa R, Rajakulasingam K, Prosperini G, Church MK, Holgate ST: Relative potencies and time course of changes in adenosine 5′-monophosphate airway responsiveness with inhaled furosemide and bumetanide in asthma. J Allergy Clin Immunol 1993, 92:288-297.
44. Rajakulasingam K, Polosa R, Church MK, Howarth PH, Holgate ST: Effect of inhaled frusemide on responses of airways to bradykinin and adenosine 5′-monophosphate in asthma. Thorax 1994, 49:485-491.
45. Crimi N, Polosa R, Prospenni G, et al.: Effect of inhaled frusemide on neurokinin A-induced bronchoconstriction in asthma. Am Rev Respir Dis 1995, 151:A108.
46. Bianco S, Robuschi M, Vaghi A, Pieroni MG, Refini RM, Sestini P: Combined treatment with inhaled furosemide and lysine acetylsalicylate in steroid-dependent asthma. Eur Respir J 1991, 4:343-344.
47. 2 against aspirin-induced asthma. Eur Respir J 1994, 7:319S.
48. Yates DH, O'Connor BJ, Yilmaz G, et al.: Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Am J Respir Crit Care Med 1995, 152:2173-2175.
49. Angus RM, Millar EA, Chalmers GW, Thomson NC: Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction. Am J Respir Crit Care Med 1995, 151:2003-2005.
50. Hatzelmann A, Tenor H, Schudt C: Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995, 114:821-831.
51. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J: Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994, 343:1006-1008.
52. Harbinson PL, Sullivan PJ, Wahid S, et al.: Effect of COP840, a selective inhibitor of phosphodiesterase type IV (PDE IV), on the allergen induced asthmatic response [abstract]. Am J Respir Crit Care Med 1996, 153:A347.
53. Santing RE, Rohof AAB, van der Zee NM, Zaagsma J: Effect of subtype selective phosphodiesterase inhibitors on allergen-induced airway obstruction, hyperreactivity and inflammation in sensitized guinea pigs [abstract]. Am J Respir Crit Care Med 1996, 153:A347.
54. Evans DJ, Aikman SL, Kharitonov SA, O'Connor BJ: Inhaled tolafentrine, a PDE III/IV inhibitor: acute effect on histamine- and AMP-induced bronchoconstriction and exhaled NO in mild asthma [abstract]. Am J Respir Crit Care Med 1996, 153:A347.
55. Ohnishi T, Kita H, Mayeno AN, et al.: Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clin Exp Immunol 1996, 104:325-331.
56. Hunt LW, Swedlund HA, Gleich GJ: Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc 1996, 71:361-368.
57. Ahmed T, Abraham WM, D'Brot J: Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 1992, 145:566-570.
58. Ahmed T, Syriste T, Lucio J, Abraham WM, Robinson M, D'Brot J: Inhibition of antigen-induced airway and cutaneous responses by heparin: a pharmacodynamic study. J Apply Physiol 1993, 74:1492-1498.
59. Ahmed T, Garrigo J, Danta I: Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993, 329:90-95.
60. Brown JK, Jones CA, Tyler CL, Ruoss SJ, Hartmann T, Caughey GH: Tryptase-induced mitogenesis in airway smooth muscle disease. Chest 1993, 107(suppl):95S-96S.
61. Barnes PJ: Is asthma a nervous disease? Chest 1995, 107:119S-125S. This review deals with information to support the role of neurogenic inflammation in the pathogenesis of asthma. Particular emphasis is place on neuropeptides neurokinin A and substance P, but with attention to the role of kinins as bradykinin and muscarinic receptors in bronchoconstriction and airway inflammation.
62. Clark JM, Abraham WM, Fishman CE, et al.: Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995, 152:2076-2083.
63. Fryer AD, Maclagan J: Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1984, 83:978-978.
64. Barnes PJ: Neural mechanisms in asthma. Br Med Bull 1992, 48:149-168.
65. Fryer AD, Jacoby DB: Parainfluenza virus infection damages inhibitory M2 muscarinic receptors on pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1991, 102:267-271.
66. Fryer AD, el-Fakahany EE, Jacoby DB: Parainfluenza virus type 1 reduces the affinity of agonists for muscarinic receptors in guinea-pig heart and lung. Eur J Pharmacol 1990, 181:51-58.
67. Jacoby DB, Gleich GJ, Fryer AD: Human eosinophil major basic protein in an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 1993, 91:1314-1318.
68. 2 receptors after the early allergic reaction: possible contribution to bronchial hyperresponsiveness in allergic guinea-pigs. Br J Pharmacol 1995, 114:881-887.
69. Takahashi T, Belvisi MG, Patel H, et al.: Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994, 150:1640-1645.
70. Nizankowska E, Soja J, Pinis G, et al.: Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995, 8:1091-1099. This study of cyclosporine in severely asthmatic subjects demonstrates that subjects on cyclosporine had improved subjective relief in terms of symptoms but no objective benefit with the drug was seen over placebo by the study's end. Cyclosporine had no significant steroid sparing effect by the end of the treatment period.
71. Migita K, Eguchi K, Kawabe Y, Tsukada T, Mizokami A, Nagataki S: FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. J Clin Invest 1995, 96:727-732.
72. Fukuda T, Asakawa J, Motojima S, Makino S: Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann Allergy Asthma Immunol 1995, 75:65-72.
73. Alexander AG, Barnes NC, Kay AB: Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992, 339:324-328.
74. Lock SH, Kay AB, Barnes NC: Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996, 153:509-514. In contrast to the study by Nizankowska et al. (Eur Respir J 1995, 8:1091-1099), this 36-week treatment period study demonstrated that cyclosporine had a significant steroid-sparing effect in 16 patients who completed the study. Morning peak expiratory flow rate was also significantly improved by those taking cyclosporine.
75. Walz DT, DiMartino MJ, Griswold DE, Intoccia AP, Flanagan TL: Biologic actions and pharmacokinetic studies in auranofin. Am J Med 1983, 75:90-107.
76. Suzuki S, Okubo M, Kaise S, Ohara M, Kasukawa R: Gold sodium thiomalate selectivity inhibits interleukin-5-mediated eosinophil survival. J Allergy Clin Immunol 1995, 96:251-256.
77. Honma M, Tamura G, Shirato K, Takishima T: Effect of an oral gold compound, auranofin, on non-specific bronchial hyperresponsiveness in mild asthma. Thorax 1994, 49:649-651.
78. Bernstein DI, Bernstein IL, Bodenheimer SS, Pietrusko RG: An open study of Auranofin in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1988, 81:6-16.
79. Nierop G, Gijzel WP, Bel EH, Zwinderman AH, Dijkman JH: Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax 1992, 47:349-354.
80. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B: A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. J Allergy Clin Immunol 1996, 98:317-324.
81. Trifilieff A, Da Silva A, Gies JP: Kinins and respiratory tract diseases. Eur Respir J 1993, 6:576-587.
82. Roisman GL, Lacronique JG, Desmazes-Dufeu N, Carre C, Le Cae A, Dusser DJ: Airway responsiveness to bradykinin is related to eosinophilic inflammation in asthma. Am J Respir Crit Care Med 1996, 153:381-390.
83. Robinson DS, Hamid Q, Ying S, et al.: Predominant TH1-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298-304.
84. Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR: Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax 1993, 48:26-32.
85. 1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995, 12:477-487.
86. Robinson DS, Ying S, Bentley AM, et al.: Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol 1993, 92:397-403.
87. 2-like" cells in allergy and asthma: pharmacological perspectives. TIPS 1994, 13:324-332.
88. Virchow J-C, Walker C, Hafner D, et al.: T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995, 151:960-986.
89. Lukacs NW, Strieter RM, Chensue SW, Kunkel SL: Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J respir Cell Mol Biol 1994, 10:526-532.
90. 2 mucosal immunity. Am J Respir Cell Mol Biol 1995, 13:54-59.
91. 2 cell inhibitor, IPD-1151T, on late asthmatic response in guinea pigs. Am J Respir Crit Care Med 1996, 153:A349.
92. Keane-Myers A, Wills-Karp M: Recombinant interferron-gamma prevents the development of allergen-induced airway hyprereactivity. Am J Respir Crit Care Med 1996, 153:A769.
93. Gater PR, Paciorek PM, Rinaidi N, Tannu SA, Renzetti LM: Inhibition of allergic bronchoconstriction and airway inflammation in the guinea-pig by IL-12 [abstract]. 1996, 153:A143.
94. Stellato C, Beck LA, Gorgone GA, et al.: Expression of the chemokine RANTES by a human bronchial epithelial cell line. J Immunol 1995, 155:410-418.
95. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R: Intercellular adhesion molecule-1 (ICAM-2) in The pathogenesis of asthma. Science 1990, 247:456-459.
96. Canonica GW, Ciprandi G, Pesce GP, Buscaglia S, Paolieri F, Bagnasco M: ICAM-1 on epithelial cells in allergic subjects: a hallmark of allergic inflammation. Int Arch Allergy Immunol 1995, 107:99-102.
97. Lukacs NW, Strieter RM, Kunkel SL: Leukocyte infiltration in allergic airway inflammation. Am J Respir Cell Mol Biol 1995, 13:1-6.
98. Bonnefoy J-Y, Aubry J-P, Gauchat J-F, et al.: Receptors for IgE. Current Opinion in Immunol 1993, 5:944-949.
99. Belvisi MG, Stretton CD, Yacoub M, Barnes PJ: Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol 1992, 210:221-222.
100. Barnes PJ: NO or no NO in asthma? Thorax 1996, 51:218-220.
101. Robbins RA, Barnes PJ, Springall DR, et al.: Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun 1994, 203:209-218.
102. Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ: Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Respir Crit Care Med 1995, 152:892-896.
103. Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM: Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995, 152:800-803.
104. Barnes PJ, Belvisi MG: Nitric oxide and lung disease. Thorax 1993, 48:1034-1043.
105. Meyers DA, Bleecker ER: Approaches to mapping genes for allergy and asthma. Am J Respir Crit Care Med 1995, 152:411-413.
106. Meyers DA, Postma DS, Panhuysen CIM, et al.: Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics 1994, 23:464-470.
107. van Herwerden L, Harrap SB, Wong ZYH, et al.: Linkage of high-affinity IgE receptor gene with bronchial hyperreactivity, even in absence of atopy. Lancet 1995, 346:1262-1265. This paper deals with an exciting area in asthma, the genetic linking of a particular gene locus with phenotypic expression of that gene complex in the form of BHR. It is of obvious interest as it ties in the high-affinity IgE receptor gene with a pathophysiologic feature of asthma and allergy.
108. Mossman BT, Mason R, McDonald JA, Gail DB: Advances in molecular genetics, transgenic models, and gene therapy for the study of pulmonary diseases. Am J Repir Crit Care Med 1995, 151:2065-2069.